KLRA - Kailera Therapeutics, Inc.

26
26.000   100.000%

Share volume: 8,114,314
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.19%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$26.00
P/E Ratio 
N/A
DAY RANGE
$23.70 - $27.50
EPS 
N/A
52 WEEK RANGE
$23.70 - $27.50
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$8,114,314
AVERAGE 30 VOLUME 
$8,114,314
Company detail
CEO: Ronald C. Renaud, Jr.
Region: US
Website: www.kailera.com
Employees: 145
IPO year: 2026
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Our principal executive offices are located in Waltham, Massachusetts.

Recent news